MedTrace Logo

Amylin-Induced Migraine Attacks Without Aura

NCT07340788 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-01-14

No results posted yet for this study

Summary

Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.

Conditions

  • Headache Disorders, Primary
  • Headache Disorders
  • Brain Diseases
  • Nervous System Diseases
  • Central Nervous System Diseases
  • Neurologic Manifestations
  • Signs and Symptoms
  • Pathological Conditions, Signs and Symptoms
  • Migraine Disorders
  • Headache
  • Pain
  • Peptide Hormones
  • Hormones
  • Hormones, Hormone Substitutes, and Hormone Antagonists
  • Peptides
  • Amino Acids, Peptides, and Proteins
  • Amylin
  • Pramlintide

Interventions

DRUG

Amylin

The participants will receive continuous intravenous infusion of 20 mL (6 μg/min) of pramlintide (amylin) over 20 minutes.

DRUG

Placebo

The participants will receive continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2028-10-30
Completion
2028-10-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07340788 on ClinicalTrials.gov